Navigation Links
DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
Date:4/26/2013

Chicago, IL (PRWEB) April 26, 2013

The birth control safety advocates at DrugRisks.com have added new information to the site for women using the contraceptives Yaz or Yasmin. A court recently ordered that Bayer no longer holds a patent on the drugs as the company continues to settle claims from patients alleging blood clot injuries**.

DrugRisks was created to give patients taking popular prescription drugs like Yaz and Yasmin the latest warnings, recalls, studies and legal news. With access to clear information, patients can discuss side effect concerns with their doctor and decide if they need legal advice.

The British Medical Journal and FDA have cautioned that birth control pills containing drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%*.

With a growing number of patients filing a Yaz lawsuit alleging blood clot injuries, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Now, DrugRisks has added information showing the U.S. Circuit Court of Appeals for Washington last week ruled Bayer’s patent on Yaz, which was set to expire in 2014, is no longer valid**. This will allows competitors Actavis, Sandoz and Lupin to continue selling their generic versions of the drug**.

Bayer’s latest financial reports show the company has spent nearly $1 billion to settle around 4,800 claims alleging Yaz blood clots, and will continue to evaluate new claims for settlement on a case-by-case basis***.

Lawyers are still helping those affected file a claim. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisks Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal MDL drug injury cases, DrugRisks cautions that patients should seek a lawyer with experience in this litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

Visit http://www.DrugRisks.com today for more information on the research, Yaz side effects and litigation news related to Yaz or Yasmin, or to speak with a lawyer.

*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
**businessweek.com/news/2013-04-16/bayer-patent-on-yaz-birth-control-pill-ruled-invalid
***Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, February 28, 2013

Read the full story at http://www.prweb.com/releases/yaz-side-effects/2013-settlement-news/prweb10662368.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
2. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
3. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
4. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
5. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
6. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
7. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
8. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
9. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
10. Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Some CasesDismissed from Consolidated Litigation
11. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine & ... that earned the designation of High Performing Hospitals by U.S. News & World Report ... a hospital was significantly better than the national average in a given procedure ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... that has been named to the 2017 Inc. 500|5000, an exclusive ranking of ... three-year growth rate of 139 percent, marking the twelfth year that the company ...
(Date:8/23/2017)... Nashville, Tennessee (PRWEB) , ... August 23, 2017 ... ... expand its team to support long-term strategic growth plans, announcing the hiring of ... , A certified technology consultant and seasoned sales manager, Keelan will be working ...
(Date:8/23/2017)... ... August 23, 2017 , ... A ... of Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an ... According to the report, a wider scope of physical therapy options is showing ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... collection of unique masks and serums that perfectly fuse the beauty of naturally ... at the 2017 Indie Beauty Expo on August 23rd & 24th in New ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
Breaking Medicine Technology: